The Medicines Company and Daiichi Sankyo Announce Angiox(R) (Bivalirudin) Co-Promotion for Germany

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Algemeen advies 01/11/2011 06:56
PARSIPPANY, NJ, Oct 28, 2011 (MARKETWIRE via COMTEX) --
. The Medicines Company (Deutschland) GmbH (NASDAQ: MDCO) and Daiichi Sankyo Deutschland GmbH today announced a co-promotion for Angiox(R) (bivalirudin) in Germany, beginning on November 1, 2011.

Angiox is The Medicines Company's injectable direct thrombin inhibitor indicated in Europe as an anticoagulant for adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-elevation MI (STEMI) undergoing primary PCI. Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation MI (NSTEMI) planned for urgent or early intervention. The product carries a Class 1B recommendation from the European Society of Cardiology in both Germany and Europe for use in patients with STEMI and NSTEMI undergoing PCI.

The companies estimate that the partnership will enable 100% combined service coverage for hospitals in Germany that provide interventional cardiology services and manage acute coronary syndromes -- the key indication areas for Angiox.

Wolfgang Hecht, leader of The Medicines Company team in Germany, commented, "This co-promotion is an important way for The Medicines Company to strengthen its presence in Germany and Europe. Germany is Europe's largest acute cardiovascular market and has leading cardiology science and sophisticated economic demands. We expect that combining the studies of Angiox in German cardiology centers with Daiichi Sankyo's established presence in acute care cardiology will accelerate patient access to PCI treatment with Angiox."

Ralf Goeddertz, Managing Director of Daiichi Sankyo Germany, commented, "With Angiox, we achieve an even stronger position in cardiology and have the opportunity to expand our reputation as a competent partner for hospitals and cardiologists."

Oliver Appelhans, Manager Country Operations of Daiichi Sankyo Deutschland GmbH, added: "This partnership with The Medicines Company potentially generates added value for German patients with acute coronary syndromes. Angiox is an excellent addition to our therapeutic offerings. Furthermore, our customers now have the opportunity to benefit from the combined support of both companies."

About The Medicines Company
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.

About Angiox(R) (bivalirudin)
In Europe, Angiox currently is indicated as an anticoagulant for adult patients undergoing PCI, including patients with STEMI undergoing primary PCI. Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation MI planned for urgent or early intervention. Please see full prescribing information available at http://www.angiox.com



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL